Next Article in Journal
Assessment of the Evolution of Cancer Treatment Therapies
Next Article in Special Issue
The Many Faces of Wnt and Pancreatic Ductal Adenocarcinoma Oncogenesis
Previous Article in Journal
Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans
Previous Article in Special Issue
Dual Targeting of the Insulin-Like Growth Factor and Collateral Pathways in Cancer: Combating Drug Resistance
Cancers 2011, 3(3), 3242-3278; doi:10.3390/cancers3033242
Review

Aberrant Signaling Pathways in Glioma

1,* , 1
, 1
, 1
, 1,2
, 1
 and 1
Received: 12 July 2011; in revised form: 1 August 2011 / Accepted: 3 August 2011 / Published: 10 August 2011
(This article belongs to the Special Issue Cancer Signaling Pathways and Crosstalk)
View Full-Text   |   Download PDF [1381 KB, uploaded 10 August 2011]   |   Browse Figures
Abstract: Glioblastoma multiforme (GBM), a WHO grade IV malignant glioma, is the most common and lethal primary brain tumor in adults; few treatments are available. Median survival rates range from 12–15 months. The biological characteristics of this tumor are exemplified by prominent proliferation, active invasiveness, and rich angiogenesis. This is mainly due to highly deregulated signaling pathways in the tumor. Studies of these signaling pathways have greatly increased our understanding of the biology and clinical behavior of GBM. An integrated view of signal transduction will provide a more useful approach in designing novel therapies for this devastating disease. In this review, we summarize the current understanding of GBM signaling pathways with a focus on potential molecular targets for anti-signaling molecular therapies.
Keywords: glioblastoma; signaling; proliferation; invasion; angiogenesis; molecular target glioblastoma; signaling; proliferation; invasion; angiogenesis; molecular target
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Nakada, M.; Kita, D.; Watanabe, T.; Hayashi, Y.; Teng, L.; Pyko, I.V.; Hamada, J.-I. Aberrant Signaling Pathways in Glioma. Cancers 2011, 3, 3242-3278.

AMA Style

Nakada M, Kita D, Watanabe T, Hayashi Y, Teng L, Pyko IV, Hamada J-I. Aberrant Signaling Pathways in Glioma. Cancers. 2011; 3(3):3242-3278.

Chicago/Turabian Style

Nakada, Mitsutoshi; Kita, Daisuke; Watanabe, Takuya; Hayashi, Yutaka; Teng, Lei; Pyko, Ilya V.; Hamada, Jun-Ichiro. 2011. "Aberrant Signaling Pathways in Glioma." Cancers 3, no. 3: 3242-3278.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert